MAP
BTAI icon

Moody Aldrich Partners’s BioXcel Therapeutics BTAI Stock Holding History

Moody Aldrich Partners’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,265
Closed -$874K – 177
2021
Q1 		$874K Buy
1,265
+20
+2% +$16.1K 0.13% 130
2020
Q4 		$920K Buy
1,245
+3
+0.2% +$2.34K 0.15% 120
2020
Q3 		$862K Buy
1,242
+31
+3% +$23.3K 0.18% 109
2020
Q2 		$1.03M Sell
1,211
-3,767
-76% -$2.46M 0.22% 104
2020
Q1 		$1.78M Buy
+4,978
New +$1.79M 0.54% 71

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Moody Aldrich Partners's BTAI Position: Q2 2021 in Review

Moody Aldrich Partners sold out of BioXcel Therapeutics (BTAI) in Q2 2021, closing a stake of 1,265 shares — an estimated $874K sold.

Moody Aldrich Partners first reported a position in BTAI in Q1 2020 and held it in 5 quarters. The position peaked at $1.78M in Q1 2020. 108 funds tracked by Wall St. Rank hold BTAI as of Q2 2021.

  • Moody Aldrich Partners reported no remaining BioXcel Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Moody Aldrich Partners sold 1,265 BioXcel Therapeutics shares in Q2 2021, an estimated $874K.
  • Moody Aldrich Partners first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 5 quarters.
  • Moody Aldrich Partners's BioXcel Therapeutics position peaked at $1.78M in Q1 2020.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2021.

Based on Moody Aldrich Partners's 13F filing for Q2 2021, filed 4 Aug 2021.